Universidade do Estado do Amazonas, Departamento de Medicina, Manaus, AM, Brasil.
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Programa de Pós-Graduação em Medicina Tropical, Manaus AM, Brasil.
Rev Soc Bras Med Trop. 2020 Oct 21;53:e20200333. doi: 10.1590/0037-8682-0333-2020. eCollection 2020.
Achieving viral suppression (VS) in children is challenging despite the exponential increase in access to antiretroviral therapy (ART). We evaluated VS in children >1 year of age and adolescents 5 years after they had begun ART, in Manaus, Amazonas state, Brazil.
HIV-infected, ART-naive children >1 year of age between 1999 and 2016 were eligible. Analysis was stratified by age at ART initiation: 1-5 y, >5-10 y, and >10-19 y. CD4+ T-cell count and viral load were assessed on arrival at the clinic, on ART initiation, and at 6 months, 1 year, 2 years, and 5 years after ART initiation. The primary outcome was a viral load <50 copies/mL 5 years after ART initiation.
Ultimately, 121 patients were included. The mean age at diagnosis was 4.8 years (SD 3.5), mean CD4% was 17.9 (SD 9.8), and mean viral load was 4.6 log10 copies/ml (SD 0.8). Five years after ART initiation, the overall VS rate was 46.9%. VS by patient age group was as follows: 36.6% for 1-5 y, 53.3% for >5-10 y, and 30% for >10-19 y. Almost all children (90,4%) showed an increase in CD4%+ T cell count. There were no statistically significant predictors for detecting children who do not achieve VS with treatment. VS remained below 65% in all the evaluated periods.
Considerable immunological improvement is seen in children after ART initiation. Further efforts are needed to maintain adequate long-term VS levels and improve the survival of this vulnerable population.
尽管抗逆转录病毒疗法(ART)的可及性呈指数级增长,但儿童实现病毒抑制(VS)仍然具有挑战性。我们评估了巴西亚马逊州玛瑙斯市 1 岁以上儿童和开始 ART 后 5 年的青少年的 VS。
1999 年至 2016 年,符合条件的是 HIV 感染、ART 初治的 1 岁以上儿童。分析按 ART 开始年龄分层:1-5 岁、>5-10 岁和>10-19 岁。在就诊时、开始 ART 时以及开始 ART 后 6 个月、1 年、2 年和 5 年时评估 CD4+T 细胞计数和病毒载量。主要结局是 ART 开始后 5 年病毒载量<50 拷贝/ml。
最终纳入 121 名患者。诊断时的平均年龄为 4.8 岁(标准差 3.5),平均 CD4%为 17.9(标准差 9.8),平均病毒载量为 4.6 log10 拷贝/ml(标准差 0.8)。ART 开始后 5 年,总体 VS 率为 46.9%。按患者年龄组的 VS 率如下:1-5 岁组为 36.6%,>5-10 岁组为 53.3%,>10-19 岁组为 30%。几乎所有儿童(90.4%)的 CD4+T 细胞计数均增加。没有统计学上显著的预测因素可以发现未通过治疗达到 VS 的儿童。在所有评估期间,VS 均低于 65%。
ART 后儿童的免疫功能有了显著改善。需要进一步努力维持足够的长期 VS 水平并改善这一脆弱人群的生存。